NeuroDerm Ltd. was a big mover last session, as its shares rose over 15% on the day. The move came after Japan's Mitsubishi Tanabe Pharma Corp has agreed to buy Israeli drug maker Neuroderm for $1.1 billion in cash as part of its business growth strategy in the United States. This led to too far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up over 26% in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
NeuroDerm currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked stock in the Medical - Drugs space is Ritter Pharmaceuticals, Inc (RTTR - Free Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is NDRM going up? Or down? Predict to see what others think: Up or Down
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artifical intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential.
See these stocks now>>